

**BEHAVIORAL HEALTH ADMINISTRATION  
SUBSTANCE RELATED DISORDERS (SRD)  
FY 2016 GRANT APPLICATION INSTRUCTIONS**

**MFR and System Development Plan**

- a. The following Managing For Results (MFR) performance outcome measures that applied to substance related disorder treatment grants in **FY14** were:
- 1) 62% of all adult and adolescent patients in BHA funded treatment programs have a treatment episode of not less than 90 days.
  - 2) 50% of adolescent and 72% of adult patients completing/transferred/referred from BHA funded intensive outpatient programs enter another level of treatment within thirty days of discharge.
  - 3) 90% of the patients completing/transferred/referred from BHA funded residential detoxification programs enter another level of treatment within 30 days of discharge.
  - 4) The number of patients using substances at completion/transfer/referral from non-detox treatment will be reduced by 95% among adolescents and 93% among adults from the number of patients who were using substances at admission to treatment.
  - 5) The number of employed adult patients at completion/transfer/referral from non-detox treatment will increase by 32% from the number of patients who were employed at admission to treatment.
  - 6) The number arrested during the 30 days before discharge from non-detox treatment will decrease by 85% for adolescents and 92% for adults from the number arrested during the 30 days before admission.

The following additional performance measures apply to FY15 SRD treatment grants:

- a. 42% of patients dis-enrolled from a Level III.7 will enter another level of care within 30 days.
- b. 45% of patients dis-enrolled from a Level III.5 will enter another level of care within 30 days.
- c. 37% of patients dis-enrolled from a Level III.3 will enter another level of care within 30 days.

**Describe your jurisdiction's outcome measure data for the entire 12 months of FY 14 relative to the SRD MFR outcome measures. Explain variations and describe plans to address all deficiencies.**

- b. The following Managing for Results (MFR) performance measures apply to substance related disorder treatment grants in **FY15**.
- 1) 47% of all adult and adolescent patients in BHA funded treatment programs have a treatment episode of not less than 90 days.
  - 2) 66% of adolescent adult patients completing/transferred/referred from BHA funded intensive outpatient programs enter another level of treatment within thirty days of discharge.
  - 3) 90% of the patients completing/transferred/referred from BHA funded residential detoxification programs enter another level of treatment within 30 days of discharge.
  - 4) The number of patients using substances at completion/transfer/referral from non-detox treatment will be reduced by 72% among adolescents and 74% among adults from the number of patients who were using substances at admission to treatment.
  - 5) The number of employed adult patients at completion/transfer/referral from non-detox treatment will increase by 47% from the number of patients who were employed at admission to treatment.
  - 6) The number arrested during the 30 days before discharge from non-detox treatment will decrease by 85% for adolescents and adults from the number arrested during the 30 days before admission.
  - 7) The number of discharged patients leaving treatment against clinical advice will be reduced to 29%.
  - 8) The number of patients reporting tobacco use at discharge from non-detox treatment will be reduced by 27% among adolescents and 28% among adults from the number reporting tobacco use at admission.

The following additional performance measures apply to FY15 SRD treatment grants:

- a. 42% of patients dis-enrolled from a Level III.7 will enter another level of care within 30 days.
- b. 45% of patients dis-enrolled from a Level III.5 will enter another level of care within 30 days.
- c. 37% of patients dis-enrolled from a Level III.3 will enter another level of care within 30 days.

**Describe your jurisdiction's outcome measure data from the first 6 months of FY 15 relative to the SRD MFR outcome measures. Explain variations and identify plans to address all deficiencies.**